retatrutide weight loss retatrutide clinical trial Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial loss. Read about the work via the link in the comments Retatrutide, a TRIPLE agonist (GLP1,

PMID 12183643

Escalation decisions should rely on objective data rather than subjective tolerance alone

GLP-1 medications are powerful tools, but they also change the bodys training and recovery environment

Rapid inactivation of these incretin hormones by DPP-4 leads to an insufficient release of insulin following oral glucose intake [31] and many of the physiological signs of T2DM, such as deteriorating glycemic control, are secondary to incretin inactivation by DPP-4

For shift workers on weekly GLP-1 formulations, choose your injection day based on your most consistent day off

Youve read the articles about Ozempic rebound, where people gain all the weight backand sometimes morewithin a year of stopping their injections